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ABSTRACT 
Objective: Study to evaluate the role of serotonin in Parkinsonism by using olanzapine (an atypical antipsychotic drug) on haloperidol-induced 
extrapyramidal symptoms (EPS) in Swiss albino mice. 
Methods: EPS like catatonia and rigidity were produced in Swiss albino mice by intraperitoneal (i. p) injection of haloperidol. Olanzapine was given 
as a pretreatment for acute and sub-acute basis (15 d orally) and effects were compared in terms of protection against catatonia like abnormal 
movements. They were analyzed statistically by ANOVA followed by post hoc Tukey’s test using SPSS 20 software. 
Results: There was no improvement in catatonia scores on the acute study, but on subacute (15 d) intervention a moderate improvement in the 
combination group (15-20 %) was seen as compared to haloperidol alone. 
Conclusion: Low-dose olanzapine due to serotonin antagonism and probable partial D1 
Keywords: Haloperidol, Dopamine receptor subtypes (D
agonist actions may have the potential to improve the features of 
Parkinsonism. Further, it can have advantages over selective serotonin reuptake inhibitors (SSRI) for antidepressant activity in above disease. 
1 and D2), Serotonin receptor subtypes (5HT1-7
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Parkinsonism has been considered a slowly developmental 
neurodegenerative disorder with loss of the dopaminergic neurons 
of nigrostriatal tracts [1, 2]. The predominant primary features of 
Parkinsonism Disease (PD) include abnormal movements like 
akinesia, tremors and rigidity. Other than primary features, patients 
also frequently suffer from psychosis, Levodopa-Induced Dyskinesia 
(LID), dementia and depression too. The symptoms of psychosis and 
LID may be due to [3] high dopamine levels during initial periods of 
therapy while depression may be secondary to serotonin deficiency. 
The normal physiology of basal ganglion is complex [3]. There are 
serotonin projections from the dorsal horn raphe (D. H. R) to the 
basal ganglion, motor cortex and various other parts of the 
midbrain. Basal ganglion has an input unit at the level of the 
striatum. Through direct pathways involving D1 stimulatory 
receptors, it sends facilitator signals to substantia nigra pars 
reticular is (SNPR) and globes pallidum medialis (GPM) for 
thalamocortical motor activity, while through D2
The main idea which motivated us for the above work was 
marked low levels of serotonin in basal ganglion in PD patients. 
Further, a probable inhibitory effect of serotonin over dopamine 
functions has also been mentioned. So still an unresolved issue 
till date, we planned a study to evaluate the role of sub-
therapeutic dose of olanzapine (with serotonin antagonism) on 
haloperidol-induced EPS. 
MATERIALS AND METHODS 
Drugs 
Inj Serenace (Haloperidol 5 mg/ml-RPG LIFE), Tab Ozepam 
(Olanzapine 0.5 mg-INNOVA Pharmaceuticals), Distilled water (Core 
Pharmaceuticals), syringes and needles. Drugs were purchased 
through their local distributors. 
 receptors involving 
indirect pathways via globus pallidus lateralis and sub thalamic 
nucleus (GPL and STN) sends inhibitory signals to SNPR and GPM.  
These both nuclei act as output pathway for basal ganglion. Stratum 
also receives dopamine input from substantia nigra pars compacta 
(SPNC). Striatum has a further nice balance of dopamine and 
acetylcholine activity too. There is the role of other 
neurotransmitters like dopamine, glutamate, and Gamma Amino 
Butyric Acid (GABA) etc. Out of these primary features, akinesia or 
bradykinesia are due to the lack of initiative efforts brought by 
dopamine. Due to a relative excess of acetylcholine as compared to 
dopamine at striatum, rigidity and tremors are seen which are best 
treated by centrally acting anticholinergic drugs like tri 
hexyphenidyl and benztropine. 
Animals 
Adult Swiss albino mice (20-30g) of either sex were procured from 
the central animal house, M. G. M. Medical College, Indore (M. P) and 
acclimatized for a period of 7 d at room temperature (25±2 °C) and 
50±15% relative humidity. They were housed in a standard cage and 
maintained on standard pellets and water ab libitum. The animals 
were used as per standard animal care guidelines. The study was 
carried out in the department of pharmacology, M. G. M. Medical 
College Indore (M. P). The study protocol was approved by the 
institutional animal ethics committee (IAEC) registered with 
CPCSEA (Reg. No. 709). 
Methods 
It was an experimental study on Swiss albino mice, which were 
induced catatonia by using haloperidol [4]. All the drugs were 
given by intraperitoneal route (i. p) injection except subacute 
intervention where olanzapine was given orally. (i) Total no of 
mice 24 were randomly divided into 4 groups (n=6). They were 
given drugs by I. P route and treated as follows-Group I-Control-
Haloperidol (1 mg/kg). Group II-standard group-Trihexyphenidyl 
10 mg/kg and Haloperidol 1 mg/kg. Group III-Olanzapine 0.5 
mg/kg alone and Group IV-Olanzapine and Haloperidol in above 
doses. After half an h of olanzapine (test drug), Haloperidol was 
given, and catatonia responses were assessed at 1/2, 1 and 2 h 
respectively. (ii) In subacute part of study olanzapine was given by 
oral route (0.5 mg/kg) for 15 d and catatonia was reassessed in 
the above groups. In both studies, scoring was done in animals 
where catalepsy was maintained for more than 60 seconds and 
maximum time of catatonia out of 3 responses in each animal was 
compared. A cutoff time of 1100 s was kept in all the groups. 
Statistical analysis was done by ANOVA followed by posthoc 
Tukey's test. 
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Table 1: Effects of acute olanzapine on haloperidol-induced catatonia 
Group (n=6) Dose (mg/kg) Mean catatonia scores 
  30 min 60 min 120 min 
Group I-Haloperidol 1 10.5±2.2 11.22.3 11.51.5 
Group-II Haloperidol+trihexiphenidyl 1+10 3.2±0.25 3.5±1.2a 3.5±0.56a 
Group III-0lanzapine 
a 
0.5 0±00 0±00a 0±00a 
Group IV-Haloperidol+olanzapine 
a 
1+0. 5 10.5±1.2 11.56±1.33 10.35±.23 
ANOVA with multiple tukey’s test, a
 
p<0.05as compared to controls, Results show that there was no change in catatonia scores due to olanzapine at 
all intervals of time. 
Table 2: Effects of olanzapine (subacute) on haloperidol induced catatonia 
Group (n=6) Dose (mg/kg) Mean catatonia scores 
  30 min 60 min 120 min 
Group I-Haloperidol 1 10.5±1.1 11.3±1.3 9.35±1.5 
Group-II Haloperidol+trihexiphenidyl 1+10 3.5±0.57 3.3±0.25a 2.5±0.55a 
Group III–Olanzapine 
a 
0.5 0 0a 0a 
Group IV-Haloperidol+olanzapine 
a 
1+0.5 7.5±0.79 8.81±0.2a,b 7.2±1.2a,b a,b 
ANOVA with multiple Tukey’s test, a p<0.05as compared to Group I, b
 
p<0.05as compared to Group I. 
RESULTS 
Statistically, there was no significant change in catatonia scores on 
acute doses (table-1) while 15-20% reduction in catatonia scores 
(p<0.05) as compared to haloperidol alone (table-2). While onsub 
acute intervention, olanzapine significantly reduced the catatonia 
scores. Thus, as per our study it is expected to improve the primary 
symptoms of PD. The overall impact of our study shows a significant 
improvement and reduction in catatonia scores. 
DISCUSSION 
The findings, which motivated us to exactly ascertain the probable 
role of serotonin in Parkinsonism were-(i) there was marked 
decrease in the level of serotonin in various parts of brain including 
basal ganglion in PD patients [5]. (ii) Use of ondansetron (a 5HT3 
antagonist drug) as standard drug in models of drug induced EPS. 
[6].(iii) Sarizotan which is a 5HT1A 
Review of literature regarding the correlation between 
serotonin and dopamine 
agonist and recently indicated for 
the control of symptoms of PD patients [7]. 
Literature has mentioned about a probable inverse relation and 
predominant inhibitory role of serotonin over dopamine function as 
can be elicited by following examples-(1) In patients of depression 
where low levels of serotonin are responsible for sadness of mood, 
these consequently are associated with high levels of dopamine in 
the mesolimbic system and ventral prefrontal cortex (PVC) which 
may be responsible for the aggression and irritable impulsive 
behavior [8-10]. (2) Another supporting evidence arises from use of 
atypical antipsychotic drugs [11] like clozapine, olanzapine and 
risperidone, which at antipsychotic doses have more of 5HT2A/C 
blocking property as compared to dopamine (serotonin antagonism 
with consequent high dopamine levels at PFC, thus they are more 
useful in negative and cognitive symptoms) and also associated with 
less of EPS. We expect these drugs with serotonin antagonistic 
property to improve the levels of dopamine at basal ganglion too. 
5HT2A/C
(3) The treatment of depression with drugs and even Electro 
Convulsive Therapy (ECT) goes towards the common pathway of 
raising the levels of amine transmitters with consequent down 
regulation of adrenergic receptors [13]. Hence an SSRI group of 
drugs by raising serotonin, may be decreasing the release of 
dopamine with correction of aggression and emotional quieting. 
Literature has also claimed about the high incidence of PD in 
patients on prolonged therapy with SSRI. Further, there is a 
possibility of EPS with therapeutic dose of all groups of 
antidepressants, whether on short or long term use, though they 
were more with duolexitine and few with escitalopram [14]. 
 sub receptors are widely distributed and are also found at 
the level of direct pathways (fibers to thalamic unit) of basal 
ganglion, there are documented evidences of them having an 
inhibitory role over the dopamine functions through GABA [12]. 
Still, we would like to reassess the literature and analyze them- 
Evaluating the role of serotonin agonist drugs 
Various research articles [5] have mentioned about the low levels of 
serotonin and norepinephrine in basal ganglion in PD patients. 
There are experimental evidences for the release of dopamine by 
serotonin nerve endings, but still no clear cut clinical improvement 
was seen in patients. Literature has further mentioned about the 
conversion of levodopa to dopamine in serotonin neurons as a 
compensatory measure in PD and subsequent release in response to 
stimulation by serotonin agonists [15-17]. However released 
dopamine from serotonin nerve endings following stimulation by 
agonists may be acting as false neurotransmitter [18]. 
Hence the low levels of serotonin observed in postmortem studies 
may be due to simultaneous senile degenerative changes of 
serotoninergic neurons too. Further there are indirect evidences for 
dopamine agonists like ergolines due to their additional serotonin 
agonist nature may be responsible for dyskinesias and possible 
psychotic features. The literature has further mentioned about the 
possibility of serotonin having role in tremor symptoms [19] which 
again indicates that serotonin neuronal hyper excitability may also 
be responsible for part of PD features other then dopamine and 
rather serotonin antagonist drugs may have a more significant role. 
Due to senile changes low levels of serotonin markers and up 
regulation of serotonin receptors are expected [20, 21]. As above 
5HT2A/C
Olanzapine may increase the levels of dopamine levels at basal 
ganglion too at sub therapeutic doses while at therapeutic 
antipsychotic dose few extra pyramidal symptoms may be seen due 
to simultaneous block of D
 receptors hyper excitability is known to inhibit the direct 
(facilitator) pathways of dopamine system via GABA [12], 
corresponding to our results of atypical antipsychotic drugs by 
similar effects may favor the dopamine release to some extent for 
the help of PD.  
2 receptors. Literature has mentioned 
about the differential actions of olanzapine on D2 and D1
Hence on current date instead of serotonin agonists, serotonin 
antagonistic drugs may probably have better outcomes as 
regards the improvement of PD. So further clinical trials have to 
be conducted to compare, the better efficacy of low dose 
olanzapine over the SSRI ones for the treatment of depression. 
Olanzapine has mild anti-cholinergic property which again may 
be responsible for low EPS in addition to probable dopamine 
release as suggested by us. 
 receptors 
[22], though our results favor enhance release of dopamine at sub 
antipsychotic doses of 0.5 mg/kg in mice. 
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Regarding the use of ondansetron for EPS [6] 
5HT3 sub receptors are excitatory in the area postrema of the brain 
and responsible for nausea and vomiting. Thus serotonin 
antagonism through these receptors may also be enhancing the 
dopamine release or they may have an additional anticholinergic 
property to be helpful in catatonia. 
Use of sarizotan 
The serotonin drugs with pre synaptic 5HT1A actions may actually 
decrease the release of not only serotonin, but also of other 
neurotransmitters like dopamine, etc. with the net utility for LID and also 
psychotic features associated with levodopa therapy, but may have the 
potential to worsen the PD features. We think of 5HT1A actions, they may 
have a role in anxiety too, similar to buspirone and ipsapirone. The role 
of clozapine and mirtazapine to correct dyskinesias [23] in therapeutic 
doses can be explained due to their pre synaptic agonistic actions. For 
the same reason 5HT2A/C inverse agonists (like pamivansarin) may favor 
direct pathways (enhanced dopamine release) to help patients of PD 
[24]. Currently it has U. S FDA approved status (2014) for treatment of 
Parkinsonism Disease Psychosis (PDP). 
CONCLUSION 
The olanzapine at low dose appears to have serotonin antagonism to 
enhance dopamine release property at basal ganglion through direct 
pathways to help PD patients. Similarly, at the same dose it may 
have partial D1 agonist activity too. Though at therapeutic dose it 
has established D2 antagonism in addition to being 5HT2A/C 
antagonist. This enhanced dopamine may also be responsible for 
less frequency of EPS seen other than 5HT2sA/C antagonism. 
Still, some very useful conclusions from therapeutics point of view 
can be drawn due to overall inhibitory effects of serotonin on 
dopamine activity. 
(i) 5HT1A agonist drugs like sarizotan, buspirone and also clozapine 
too (due to additional pre synaptic actions) may be useful for LID 
and PDP, but higher doses may probably deteriorate the PD features 
due to dopamine inhibition. 
(ii) Olanzapine, in low doses by block of 5HT2A/C receptors may 
potentiate the actions of D1 agonists for help of PD patients. While 
the therapeutic dose due to D2 receptors block may produce EPS. 
Similar 5HT2A inverse drugs like pamivanserin are under clinical 
trial for role PDP and we feel they may have also role in PD 
improvement too. 
(iii) Ondansetron due to 5HT3 antagonism may improve dopamine 
levels to control EPS. This protection could also be due to its 
additional anticholinergic property too. 
(iv) 5HT4 agonists like cisapride have a role in the gastrointestinal 
tract, hence may be useful for constipation secondary to PD. 
(v) 5HT5 receptors are not found in human. 
(vi) 5HT6, 7 
1. Nyati P. Pharmacology SEED. 2
antagonists may oppose the serotonin activity at basal 
ganglion to enhance dopamine levels. If designed in the future, they 
too may have potential for the help of PD patients. Further clinical 
trials will be needed to ascertain their utility. 
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